Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings

Decibel Reports Full-Year and Fourth Quarter 2025 Results: Revenue Grows 22% to $113 Million, Issues 2026 Guidance

Decibel Cannabis Confirms AgMedica Integration Success, Extends Debt Maturity Through 2030

Executive Summary
  • Full-Year 2025 Results: Net revenue grew 22% to $113 million; Adjusted EBITDA rose 29% to $23 million. Free Cash Flow surged 292% to $5.5 million.
  • International Growth: International sales increased 484% year-over-year to $24 million, driven by AgMedica Bioscience Inc. integration.
  • AgMedica Performance: The acquired entity contributed $7 million in Adjusted EBITDA for the full year, exceeding the initial $4 million target.
  • 2026 Guidance: Company projects net revenue of $130 to $135 million (approx. 18% growth) and Adjusted EBITDA of $27 to $31 million (approx. 26% growth).
  • Operational Updates: Creston, BC property sale agreement entered for $2.5 million; consolidation into Battleford, SK facility expected to save $4 million annually.
  • Debt Refinancing: Closed a new $61 million credit facility on February 10, 2026, extending maturities to 2030 and reducing 2026 payment obligations by $5 million.
Material Impact
  • Guidance Miss vs. Revision: The actual Full-Year 2025 revenue ($113M) and EBITDA ($23M) slightly missed the revised guidance provided in Q3 2025 (Revenue ~$115M, EBITDA ~$24M). This indicates minor execution variance against internal targets but remains within a narrow margin (~2%).
  • Cash Flow Validation: The 292% surge in Free Cash Flow is the most material positive metric, confirming operational efficiency improvements and validating the debt refinancing strategy.
  • Strategic Confirmation: The AgMedica integration exceeding EBITDA targets ($7M vs $4M) confirms the acquisition thesis was sound, reducing execution risk associated with M&A.
  • Balance Sheet Health: The February 2026 debt extension and asset sale were previously announced material events; this earnings release serves as confirmation rather than introducing new capital or strategic shifts.
  • Forward Outlook: 2026 guidance implies continued growth, but the slight miss on FY2025 targets suggests management may be conservative in future projections to ensure delivery.
DB · Price
Company Overview
  • Company Profile: Decibel Cannabis Company Inc. operates in the cannabis sector with a focus on domestic brand growth and international cultivation/processing via AgMedica Bioscience Inc.
  • Flagship Project: The integration of AgMedica Bioscience Inc., which provides international GACP cultivators and processing capacity (60 Tons per Annum).
  • Domestic Brands: "Standard Issue" brand launched with early sell-through exceeding forecasts by 30%; refreshed vape portfolio including General Admission disposables.
  • Facilities: Primary cultivation consolidated into Battleford, Saskatchewan; Creston, BC facility slated for sale to optimize footprint.
Read the original news release →

More from Decibel Cannabis Company Inc.